Premium
Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1‐receptor agonist, in hypertensive patients.
Author(s) -
Weber RR,
McCoy CE,
Ziemniak JA,
Frederickson ED,
Goldberg LI,
Murphy MB
Publication year - 1988
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1988.tb03276.x
Subject(s) - fenoldopam , pharmacokinetics , agonist , medicine , pharmacodynamics , volume of distribution , pharmacology , blood pressure , chemistry , anesthesia , receptor
1 The pharmacokinetic properties of intravenous fenoldopam, a selective dopamine1‐receptor agonist, were studied in 10 patients with essential hypertension. 2 Reduction in blood pressure was linearly related to the log fenoldopam plasma concentration (r = 0.69) and the log fenoldopam infusion rate (r = 0.71). 3 The mean elimination half‐life (+/‐ s. e. mean) was 9.8 +/‐ 1.0 min. The total body clearance was 30.3 +/‐ 2.3 ml kg‐1 min‐1 and the volume of distribution was 582 +/‐ 62 ml kg‐1. 4 The rapid onset of action, short elimination half‐life, linear dose‐ response relationship, and ease of administration suggest that fenoldopam may have a role where parenteral treatment of hypertension is required.